RMAT Designation Explained: FDA Regenerative Medicine Advanced Therapy Guide

RMAT designation is an FDA expedited program created by the 21st Century Cures Act to accelerate the development and review of regenerative medicine therapies that address serious or life-threatening conditions. Enacted in December 2016, RMAT designation provides sponsors with enhanced FDA interactions, eligibility for accelerated approval and priority review, and potential access to expanded mechanisms for demonstrating product effectiveness.

For sponsors developing cell therapies, gene therapies, tissue engineering products, or combination products with regenerative medicine components, RMAT designation can significantly reduce time to market while maintaining rigorous safety and efficacy standards.

In this guide, you will learn:

• What qualifies as a regenerative medicine advanced therapy under FDA regulations
• The specific eligibility criteria for RMAT designation
• How RMAT compares to breakthrough therapy, fast track, and other expedited programs
• The RMAT designation request process and timeline expectations
• Benefits and strategic considerations for regenerative medicine sponsors

What Is RMAT Designation? Understanding Regenerative Medicine Advanced Therapy

RMAT designation is an FDA expedited pathway established under Section 3033 of the 21st Century Cures Act (Public Law 114-255). A regenerative medicine advanced therapy is a drug that meets specific criteria: it must be a regenerative medicine therapy (cell therapy, therapeutic tissue engineering product, human cell and tissue product, or combination product using such therapies), and it must be intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition.

Key characteristics of RMAT designation:

• Created specifically for regenerative medicine therapies under the 21st Century Cures Act
• Applies to cell therapies, gene therapies, tissue engineering products, and certain combination products
• Requires preliminary clinical evidence indicating potential to address unmet medical needs
• Provides enhanced FDA communication and meeting opportunities

The distinction between RMAT and other expedited programs is important: while breakthrough therapy designation is available to any drug or biologic, RMAT designation is specifically reserved for regenerative medicine therapies as defined in the statute.

RMAT FDA: How the Program Works

The RMAT FDA program operates through the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), depending on the product type. Most regenerative medicine products are regulated by CBER, though some combination products may involve CDER.

RMAT Program Structure

Regenerative Medicine Therapy Definition

Under the 21st Century Cures Act, a regenerative medicine therapy includes:

1. Cell therapy - Therapeutic products containing living cells as the active component
2. Therapeutic tissue engineering products - Products combining cells, scaffolds, and/or bioactive molecules
3. Human cell and tissue products (HCT/Ps) - Regulated under Section 361 or 351 of the PHS Act
4. Combination products - Products that combine a regenerative medicine component with a drug or device

Gene therapies are explicitly included in the regenerative medicine therapy definition, as confirmed in FDA guidance documents. This inclusion recognizes that gene therapies, like other regenerative medicines, have the potential to fundamentally alter the course of disease.

RMAT Designation Requirements: Eligibility Criteria

To qualify for RMAT designation, a product must meet two primary eligibility requirements established by the 21st Century Cures Act and clarified in FDA guidance.

Requirement 1: Product Must Be a Regenerative Medicine Therapy

The product must qualify as a regenerative medicine therapy, which includes:

Requirement 2: Addresses Serious or Life-Threatening Condition

The therapy must be intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. FDA defines "serious condition" as a disease or condition associated with morbidity that has substantial impact on day-to-day functioning.

Requirement 3: Preliminary Clinical Evidence of Potential

The therapy must show preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for such disease or condition. This standard differs from breakthrough therapy, which requires clinical evidence of substantial improvement.

Clinical Evidence Standards for RMAT:

“

Key Distinction: RMAT requires preliminary clinical evidence of "potential to address unmet medical needs," which is a lower evidentiary bar than breakthrough therapy's requirement for "substantial improvement over existing therapies."

Regenerative Medicine Designation: Comparison with Other FDA Expedited Programs

Understanding how regenerative medicine designation (RMAT) compares to other FDA expedited programs helps sponsors select the most appropriate pathway for their product.

RMAT vs. Breakthrough Therapy vs. Fast Track

Benefits Unique to RMAT

RMAT designation provides benefits that overlap with, but also extend beyond, other expedited programs:

1. All Benefits of Breakthrough Therapy Designation

• Intensive FDA guidance on efficient drug development
• Organizational commitment involving senior FDA managers
• Eligibility for rolling review (submission of BLA sections as completed)
• Eligibility for priority review (6-month review clock vs. 10 months)
• Eligibility for accelerated approval based on surrogate endpoints

2. Additional RMAT-Specific Benefits

• Early interactions to discuss potential surrogate or intermediate endpoints
• Discussions on ways to support accelerated approval
• Potential for expanded flexibility in accelerated approval requirements

When to Pursue RMAT vs. Breakthrough Therapy

“

Strategic Note: Products can receive multiple expedited designations simultaneously. Many sponsors pursue both RMAT and breakthrough therapy designation to maximize available benefits and FDA interactions.

RMAT Designation Application Process

The application process for RMAT designation follows a structured pathway with defined timelines and submission requirements.

Step 1: Determine Eligibility

Before submitting an RMAT request, confirm:

• Product meets the regenerative medicine therapy definition
• Target indication is serious or life-threatening
• Preliminary clinical evidence is available
• An active IND is on file with FDA

Step 2: Prepare the RMAT Request

An RMAT designation request should include:

Step 3: Submit to FDA

Submit the RMAT request to the appropriate FDA center:

• CBER submissions: Submit as an IND amendment with clear identification as RMAT request
• CDER submissions: Follow similar process for applicable combination products

Step 4: FDA Review and Response

FDA aims to respond to RMAT requests within 60 calendar days of receipt. The response will either grant RMAT designation, deny the request with explanation, or request additional information.

Step 5: Post-Designation Activities

Once RMAT designation is granted:

• Schedule meetings to discuss development program
• Discuss potential surrogate or intermediate endpoints
• Explore accelerated approval pathway requirements
• Begin rolling BLA submission if appropriate

Benefits of RMAT Designation for Regenerative Medicine Sponsors

Obtaining RMAT designation provides tangible benefits throughout the drug development lifecycle.

Development Phase Benefits

Review Phase Benefits

Strategic Benefits

1. Investor confidence - RMAT designation signals FDA recognition of product potential
2. Partnership value - Enhances attractiveness for licensing and collaboration
3. Competitive positioning - Demonstrates regulatory progress to stakeholders
4. Development efficiency - FDA alignment reduces costly pivots and delays

RMAT Designation Statistics and Trends

Understanding the landscape of RMAT designation helps sponsors benchmark their programs and set realistic expectations.

RMAT Designations Over Time

Since the RMAT program launched following the enactment of the 21st Century Cures Act in December 2016, the number of RMAT requests has grown steadily year over year as more sponsors develop regenerative medicine therapies. FDA publishes periodic updates on expedited program statistics, and sponsors should consult the CBER website and FDA annual reports for the most current data on RMAT designation activity.

RMAT Designations by Product Type

Gene therapies and cell therapies represent the majority of RMAT designations, consistent with the program's focus on regenerative medicine. Tissue engineering products and combination products also qualify, though they represent a smaller share of total designations. Consult FDA's CBER website for current breakdowns by product type.

RMAT Designations by Therapeutic Area

Oncology and rare genetic diseases represent the largest therapeutic areas for RMAT designations, reflecting the active development pipelines in cell and gene therapy for these indications. Other therapeutic areas including ophthalmology, cardiovascular, and neurology have also seen RMAT designation activity. FDA periodically publishes updates on designation trends by therapeutic area.

Common RMAT Designation Challenges and Solutions

Challenge 1: Insufficient Clinical Evidence

Problem: Sponsors request RMAT too early without adequate clinical data.

Solution:

• Wait for meaningful clinical signal, even from small Phase 1 studies
• Include mechanistic rationale linking preclinical to clinical observations
• Consider compassionate use data if available

Challenge 2: Unclear Unmet Medical Need Justification

Problem: Request does not adequately establish unmet medical need in target population.

Solution:

• Thoroughly document current treatment landscape
• Quantify limitations of existing therapies with data
• Describe patient population with no satisfactory options

Challenge 3: Product Definition Issues

Problem: Product does not clearly qualify as regenerative medicine therapy.

Solution:

• Obtain pre-submission feedback from FDA on product classification
• Clearly describe the regenerative medicine component
• For combination products, emphasize the regenerative medicine aspect

Challenge 4: Misunderstanding of Clinical Evidence Standard

Problem: Sponsors believe they must show substantial improvement (breakthrough standard) rather than potential to address unmet needs (RMAT standard).

Solution:

• Understand that RMAT has a lower evidentiary threshold than breakthrough therapy
• Focus on demonstrating "potential" rather than proven superiority
• Include preliminary efficacy signals even if not statistically significant

Key Takeaways

Next Steps

Obtaining RMAT designation can significantly accelerate your regenerative medicine therapy's path to approval. The enhanced FDA interactions and access to expedited review mechanisms help sponsors navigate the complex regulatory landscape for cell therapies, gene therapies, and tissue engineering products.

Organizations managing regulatory submissions benefit from automated validation tools that catch errors before gateway rejection. Assyro's AI-powered platform validates eCTD submissions against FDA, EMA, and Health Canada requirements, providing detailed error reports and remediation guidance before submission.

Sources